Versor Investments LP Decreases Stake in Pfizer Inc. $PFE

Versor Investments LP trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 68.8% in the third quarter, HoldingsChannel.com reports. The fund owned 17,126 shares of the biopharmaceutical company’s stock after selling 37,800 shares during the period. Versor Investments LP’s holdings in Pfizer were worth $436,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Peak Asset Management LLC raised its stake in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the period. Community Bank & Trust Waco Texas increased its holdings in Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares during the last quarter. Able Wealth Management LLC raised its position in Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 413 shares during the period. CVA Family Office LLC boosted its stake in Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 413 shares during the last quarter. Finally, Boltwood Capital Management increased its stake in shares of Pfizer by 0.7% during the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. Daiwa America lowered Pfizer from a “strong-buy” rating to a “hold” rating in a report on Thursday. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.00.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Post-earnings bullishness: unusual call-option activity and an upbeat earnings outlook have put some investors on the buy side, supporting short-term sentiment. Read More.
• Positive Sentiment: Investor commentary sees a buying opportunity after the quarter — analysts and commentators highlight attractive valuation and the company’s ability to generate cash as reasons to consider PFE after results. Read More.
• Positive Sentiment: Capital return profile: coverage notes Pfizer returned about $9.8B to shareholders and remains a high-yield candidate for income investors, which supports the stock’s floor for dividend-seeking buyers. Read More. Read More.
• Positive Sentiment: Dividend/yield appeal: Pfizer appears on lists of high-yield dividend names, attracting income-focused investors even as growth questions persist. Read More.
• Neutral Sentiment: Longer-term growth outlook is mixed — analyses examine whether newly acquired and in‑pipeline drugs can offset a looming 2026–2030 patent cliff; outcome will determine medium-term revenue trajectory. Read More.
• Neutral Sentiment: “Is now the best time to buy?” pieces suggest re-evaluating Pfizer after earnings — these are informative to investors but stop short of a consensus buy/sell signal. Read More.
• Negative Sentiment: Analyst downgrade: Daiwa cut Pfizer from “outperform” to “neutral” and set a $27 price target, signaling limited near-term upside from their perspective and adding downward pressure. Read More.
• Negative Sentiment: Valuation / structural concerns: opinion pieces argue Pfizer could be a value trap if new product flow and M&A don’t offset fading COVID-era sales and patent expiries, which raises caution among some investors. Read More.

Pfizer Stock Performance

NYSE:PFE opened at $27.47 on Friday. The firm has a market cap of $156.16 billion, a PE ratio of 20.19 and a beta of 0.47. The business has a 50 day moving average price of $25.77 and a 200-day moving average price of $25.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the firm earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.